51 Quotes by Barbara Ryan

The only company which is a clear growth vehicle in our view is Schering-Plough.

The only way this company can improve their earnings is through pursuing a merger or by being acquired. It's not very innovative, but it's what they're going to have to do.

So far the integration appears to be going well. The economics of the merger are going to be quite strong. We're somewhat disappointed in the near-term revenue trend and are neutral on the stock in the short run.

modest positive for the stock, modest because they have 6,000 cases behind this one.

New drugs are not going to build billion dollar sales in a few weeks. It takes years to do that.

Obviously, it's a huge market and it's growing.

Pfizer clearly is a company with tremendous disregard for the generic drug industry and is not given to settling. But it is not altogether unlikely that Pfizer could settle its litigation. If Pfizer could translate some of its cash hoards into greater certainty on this litigation ... I think they would do that.

Fourth-quarter 2005 sales of key brands were generally below our forecasts.

If it's universally recommended then obviously people are going to be getting the vaccine much more broadly.